When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...
Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...
Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...
APAC biopharma has stopped being a cost line in somebody else’s budget. For two decades the region supplied ingredients, capacity and inexpensive trial sites. The companies that used them were headquartered elsewhere. That relationship has now inverted. The clearest...
“But what can this AI model actually do?” It’s a common question being asked across the life sciences industry. Can it classify a symptom, summarize a trial record, predict a molecule’s behavior, or monitor a manufacturing process? Those capabilities matter, but they...
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....
Pharma generates more insight than ever. Translating that insight into timely action is where the system falters, and the gap runs deeper than most commercial leaders are willing to admit. Over the past decade, omnichannel systems have matured considerably. CRM...
The biopharma industry is at an inflection point as it enters 2026. Discoveries from the past year will be applied and scaled, particularly across AI-enabled drug development, advanced modalities and cardiometabolic disease treatment. These advancements will occur...
GLP-1 medications have changed the landscape of weight management. For many people, they have delivered clinically meaningful weight loss alongside improvements in glycaemic control, and their place in treatment pathways is now well established. What is becoming...
Against a backdrop of rising development and launch costs, growing regulatory complexity, geopolitical uncertainty and intensifying competition for specialist talent, many European pharma and biotech companies are reassessing the long-held ambition of “cracking the...
Johnson & Johnson has announced plans to invest more than $1 billion in a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. This project marks a significant expansion of its advanced therapies infrastructure and reinforces the company’s...